

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013								
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>
Bladder, Urinary					Melanoma of Skin			
Male	27	30.7	87.8	(57.9-127.8)	Male	18	19.2	93.6
Female	5	10.8	46.3	(14.9-108.2)	Female	15	14.5	103.1
Brain and Other Nervous System					Multiple Myeloma			
Male	9	5.5	162.8	(74.3-309.2)	Male	7	6.1	115.7
Female	4	4.5	nc	(nc-nc)	Female	3	4.8	nc
Breast					Non-Hodgkin Lymphoma			
Male	0	1.0	nc	(nc-nc)	Male	21	17.0	123.7
Female	127	115.4	110.0	(91.7-130.9)	Female	14	14.7	95.0
Cervix Uteri					Oral Cavity & Pharynx			
Female	2	3.8	nc	(nc-nc)	Male	12	13.1	91.9
Colon / Rectum					Female	5	6.2	80.8
Male	31	32.0	96.9	(65.8-137.5)	Ovary			
Female	27	31.7	85.3	(56.2-124.1)	Female	7	10.2	68.4
Esophagus					Pancreas			
Male	3	7.8	nc	(nc-nc)	Male	12	10.5	113.8
Female	0	2.0	nc	(nc-nc)	Female	10	10.6	94.5
Hodgkin Lymphoma					Prostate			
Male	1	2.2	nc	(nc-nc)	Male	97	94.8	102.3
Female	1	1.7	nc	(nc-nc)	Stomach			
Kidney & Renal Pelvis					Male	3	7.0	nc
Male	20	15.6	128.0	(78.2-197.7)	Female	4	4.1	nc
Female	5	9.3	53.5	(17.2-124.9)	Testis			
Larynx					Male	3	3.9	nc
Male	3	4.5	nc	(nc-nc)	Thyroid			
Female	1	1.4	nc	(nc-nc)	Male	12	6.9	172.9
Leukemia					Female	28	20.7	135.5
Male	17	11.9	142.6	(83.0-228.3)	Uteri Corpus and Uterus, NOS			
Female	7	8.5	82.7	(33.1-170.4)	Female	31	25.9	119.6
Liver and Intrahepatic Bile Ducts					All Sites / Types			
Male	10	10.0	100.1	(47.9-184.1)	Male	394	385.3	102.2
Female	3	3.4	nc	(nc-nc)	Female	392	394.2	99.5
Lung and Bronchus					95% CI			
Male	40	54.5	73.4	(52.5-100.0)				
Female	63	58.3	108.1	(83.1-138.3)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;